S10 Ep30: Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors
OncLive On Air
by OncLive® On Air
8h ago
Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors ..read more
Visit website
S10 Ep29: Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
OncLive On Air
by OncLive® On Air
1w ago
Drs Merkow and Connell discuss reasons why they adopted HAI therapy as a treatment offering for patients with CRC, characteristics of patients who are good candidates for this treatment, and the ability of the HAI pump to treat liver micrometastases ..read more
Visit website
S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
OncLive On Air
by OncLive® On Air
2w ago
Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy ..read more
Visit website
S10 Ep26: Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
OncLive On Air
by OncLive® On Air
3w ago
Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age ..read more
Visit website
S10 Ep25: Breast Cancer Experts Share Obstacles and Successes as Women in Oncology
OncLive On Air
by OncLive® On Air
3w ago
Drs Graff, Mahtani, McCann, and Rugo shared moments throughout their lives and careers that sparked their interest in oncology, setbacks they overcame when building their careers, obstacles they encounter as women in the field, and ways that gender bias can be confronted at both the individual and institutional levels ..read more
Visit website
S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL
OncLive On Air
by OncLive® On Air
1M ago
Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and unique mechanism of action; and key efficacy and safety data from the PhALLCON trial supporting this regulatory decision ..read more
Visit website
S10 Ep24: Schmid Summarizes Updates in HER2-Positive Breast Cancer Management
OncLive On Air
by OncLive® On Air
1M ago
Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice ..read more
Visit website
S10 Ep23: Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
OncLive On Air
by OncLive® On Air
1M ago
Dr Wagner discusses current unmet needs for patients with PEComa, how ongoing research aims to address some of these gaps, and how findings from the AMPECT trial in particular support the use of nab-sirolimus in patients with advanced malignant disease ..read more
Visit website
S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
OncLive On Air
by OncLive® On Air
1M ago
Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer ..read more
Visit website
S10 Ep21: Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas
OncLive On Air
by OncLive® On Air
1M ago
Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas ..read more
Visit website

Follow OncLive On Air on FeedSpot

Continue with Google
Continue with Apple
OR